Sensata Technologies Holding plc (ST)
NYSE: ST · Real-Time Price · USD
33.14
+2.05 (6.59%)
Aug 13, 2025, 4:00 PM - Market closed
Achilles Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts that cover Achilles Therapeutics stock have a consensus rating of "Buy" and an average price target of $33.38, which forecasts a 0.72% increase in the stock price over the next year. The lowest target is $23 and the highest is $45.
Price Target: $33.38 (+0.72%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Achilles Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 3 | 3 |
| Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Hold | 7 | 7 | 8 | 8 | 9 | 9 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 14 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Hold Maintains $27 → $35 | Hold | Maintains | $27 → $35 | +5.61% | Jul 30, 2025 |
| UBS | UBS | Strong Buy Maintains $41 → $43 | Strong Buy | Maintains | $41 → $43 | +29.75% | Jul 30, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $30 → $33 | Hold | Maintains | $30 → $33 | -0.42% | Jul 30, 2025 |
| Evercore ISI Group | Evercore ISI Group | Hold Maintains $27 → $30 | Hold | Maintains | $27 → $30 | -9.47% | Jul 30, 2025 |
| JP Morgan | JP Morgan | Sell Maintains $23 → $32 | Sell | Maintains | $23 → $32 | -3.44% | Jul 17, 2025 |
Financial Forecast
Revenue This Year
3.78B
from 3.93B
Decreased by -3.91%
Revenue Next Year
3.94B
from 3.78B
Increased by 4.18%
EPS This Year
3.36
from 0.85
Increased by 295.53%
EPS Next Year
3.62
from 3.36
Increased by 7.68%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.0B | 4.2B | 4.5B | ||
| Avg | 3.8B | 3.9B | 4.2B | ||
| Low | 3.5B | 3.6B | 3.8B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.5% | 12.0% | 15.1% | ||
| Avg | -3.9% | 4.2% | 5.7% | ||
| Low | -10.4% | -5.6% | -3.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.63 | 4.31 | 4.99 | ||
| Avg | 3.36 | 3.62 | 4.05 | ||
| Low | 3.09 | 3.18 | 3.48 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 326.5% | 28.1% | 37.7% | ||
| Avg | 295.5% | 7.7% | 11.9% | ||
| Low | 263.2% | -5.6% | -3.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.